1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Chemotherapy Induced Peripheral Neuropathy (CIPN) - Epidemiology Forecast–2030

Chemotherapy Induced Peripheral Neuropathy (CIPN) - Epidemiology Forecast–2030

  • December 2020
  • 55 pages
  • ID: 5993622
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Chemotherapy Induced Peripheral Neuropathy (CIPN) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the CIPN, historical and forecasted epidemiology as well as the CIPN trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Chemotherapy Induced Peripheral Neuropathy (CIPN) Disease Understanding
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinum-containing agents, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors. CIPN occurs in ~20% of patients given standard doses of chemotherapy and in almost 100% of patients treated with high doses.
CIPN presents clinically as deficits in sensory, motor, and sometimes autonomic function. Sensory disturbances range from a mild tingling sensation to spontaneous burning pain and hypersensitivity to stimuli.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of CIPN, Severity Specific Incident Population of CIPN, Incident Population of CIPN by Chemotherapeutic Agents, and Incident Population of CIPN by Cancer Type scenario of CIPN in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Detailed Epidemiology Segmentation
• The United States showed the highest incident population of CIPN. As per The analyst estimates, the US accounts for approximately 41.11% of total cases, for CIPN, in the 7MM countries. In 2017, the incident population of CIPN in the US was found to be 598,908.
• In 2017, incident cases of mild, moderate and severe CIPN in the US were 173,683, 305,443, and 119,782 respectively. Assessments as per analysts show that the overall incidence of moderate CIPN was maximum, followed by mild and severe, and is subjected to increase rapidly in the coming years.
• In 2017, the incident population of CIPN in the US by cancer type was accounted for 82,082 for Breast Cancer, 60,620 for colorectal cancer. CIPN in Lung Cancer patients were estimated to be 48,724 in 2017
• Among the European countries, Germany had the highest incident population of CIPN with 165,095 cases, followed by the United Kingdom which had the incident population of 120,624 in 2017. On the other hand, Spain had the lowest incident population of 73,071 in 2017.
• As per estimates, Japan accounts for approximately 18.11% of the total incident cases in the 7MM. In 2017, the incident population of CIPN in Japan was found to be 263,842.

Scope of the Report
• The report covers the descriptive overview of CIPN, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of CIPN.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of CIPN, Severity Specific Incident Population of CIPN, Incident Population of CIPN by Chemotherapeutic Agents, and Incident Population of CIPN by Cancer Type.

Report Highlights
• 11-Year Forecast of CIPN
• 7MM Coverage
• Total Incident Cases of CIPN
• Severity Specific Incident Population of CIPN
• Incident Population of CIPN by Chemotherapeutic Agents
• Incident Population of CIPN by Cancer Type

Key Questions Answered
• What are the disease risk and burden of CIPN?
• What is the historical CIPN patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of CIPN at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CIPN?
• Out of the above-mentioned countries, which country would have the highest incident population of CIPN during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Chemotherapy Induced Peripheral Neuropathy (CIPN) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM CIPN epidemiology forecast.
• The CIPN epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The CIPN epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

HER2-Positive Breast Cancer - Epidemiology Forecast to 2030

  • $ 3995
  • August 2021
  • 61 pages

HER2-Positive Breast Cancer - Epidemiology Forecast to 2030 Summary Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all ...

  • United States
  • United Kingdom
  • Breast Cancer
  • Epidemiology
  • Industry analysis
  • Cancer Incidence
  • Overweight Prevalence

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on